An outpatient-based clinical program for type 2 diabetes prevention

Endocrine Practice

Volumn 16, Issue 1, 2010, Pages 21-29

  Bersoux, Sophie ^a   Asbury, Kara L ^a   Cook, Curtiss B ^a   Verheijde, Joseph L ^a   Larson, Marcia H ^a   Aponte Furlow, Ruth T ^a   Flatten, Sandra S ^a   Hooley, Susan A ^a   LaRosa, Carolyn S ^a   Seifert, Karen M ^a   Verona, Patricia M ^a   Castro, Janna C ^a   Jameson, Kimberly A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THYROTROPIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BALANCE DISORDER; BLOOD CELL COUNT; BLOOD CHEMISTRY; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); DIET EXERCISE ACTIVITY LIFESTYLE; DIET RESTRICTION; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; GAIT DISORDER; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PATIENT EDUCATION; PATIENT PARTICIPATION; PATIENT SATISFACTION; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PHYSICAL DISEASE; PHYSIOTHERAPY; PREVALENCE; PRIMARY PREVENTION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CHANGE;

DIABETES MELLITUS, TYPE 2; DIET; EXERCISE; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; LIFE STYLE; MALE;

EID: 77649146810     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP09151.OR     Document Type: Article

References (33)

1. National Center for Chronic Disease Prevention and Health Promotion. 2007 National Diabetes Fact Sheet. Prevalence of impaired fasting glucose in people aged 20 years or older, United States, 2007. Available at: http://www.cdc.gov/diabetes/pubs/factsheet07.htm. Accessed May 11, 2009.
2. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: The Da Qing IGT and diabetes study. Diabetes Care. 1997;20:537-544.
3. Tuomilehto J, Lindström J, Eriksson JG, et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
4. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Eng J Med. 2002;346:393-403.
5. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V; Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49:289-297.
6. Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care. 2005;28:736-744.
7. Lipscomb ER, Finch EA, Brizendine E, Saha CK, Hays LM, Ackermann RT. Reduced 10-year risk of coronary heart disease in patients who participated in a community-based diabetes prevention program: The DEPLOY pilot study. Diabetes Care. 2009;32:394-396.
8. Johnson FR, Manjunath R, Mansfield CA, Clayton LJ, Hoerger TJ, Zhang P. High-risk individuals' willingness to pay for diabetes risk-reduction programs. Diabetes Care. 2006;29:1351-1356.
9. Pagoto SL, Kantor L, Bodenlos JS, Gitkind M, Ma Y. Translating the diabetes prevention program into a hospital-based weight loss program. Health Psychol. 2008;27:S91-S98.
10. Ackermann RT, Marrero DG. Adapting the Diabetes Prevention Program lifestyle intervention for delivery in the community: The YMCA model. Diabetes Educ. 2007;33:69,74-65,77-68.
11. Seidel MC, Powell RO, Zgibor JC, Siminerio LM, Piatt GA. Translating the Diabetes Prevention Program into an urban medically underserved community: A nonrandomized prospective intervention study. Diabetes Care. 2008;31:684-689.
12. Ackermann RT, Finch EA, Brizendine E, Zhou H, Marrero DG. Translating the Diabetes Prevention Program into the community. The DEPLOY Pilot Study. Am J Prev Med. 2009;35:357-363.
13. Aldana SG, Barlow M, Smith R, et al. The diabetes prevention program: A worksite experience. AAOHN J. 2005;53:499-505.
14. American Diabetes Association. Standards of medical care in diabetes mellitus - 2009. Diabetes Care. 2009;32(Suppl 1):S13-S61.
15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008;31(Suppl 1):S55-S60.
16. American Diabetes Association and National Institute of Diabetes Digestive and Kidney Disease. The prevention or delay of type 2 diabetes [erratum in Diabetes Care. 2002;25:947]. Diabetes Care. 2002;25:742-749.
17. Gerstein HC. Point: If it is important to prevent type 2 diabetes, it is important to consider all proven therapies within a comprehensive approach. Diabetes Care. 2007;30:432-434.
18. Tuomilehto J. Counterpoint: Evidence-based prevention of type 2 diabetes: The power of lifestyle management. Diabetes Care. 2007;30:435-438.
19. Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: Metformin treatment in persons at risk for diabetes mellitus. Am J Med. 2008;121:149-157.
20. Curb JD, Ceria-Ulep CD, Rodriguez BL, et al. Performance-based measures of physical function for high-function populations. J Amer Geriatr Soc. 2006;54:737-742.
21. Bravata DM, Smith-Spangler C, Sundaram V, et al. Using pedometers to increase physical activity and improve health: A systematic review. JAMA. 2007;298:2296-2304.
22. Merom D, Rissel C, Phongsavan P, et al. Promoting walking with pedometers in the community: The step-by-step trial. Am J Prev Med. 2007;32:290-297.
23. Singleton JR, Smith AG, Bromberg MB. Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve. 2001;24:1225-1228.
24. Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care. 2001;24:1448-1453.
25. Oyer DS, Saxon D, Shah A. Quantitative assessment of diabetic peripheral neuropathy with use of the clanging tuning fork test. Endocr Pract. 2007;13:5-10.
26. Rhee MK, Slocum W, Ziemer DC, et al. Patient adherence improves glycemic control. Diabetes Educ. 2005;31:240-250.
27. Lindström J, Ilanne-Parikka P, Peltonen M et al; Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: Follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673-1679.
28. Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: A 20-year follow-up study. Lancet. 2008;371:1783-1789.
29. Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: A randomized controlled trial. JAMA. 2008;299:185-193.
30. Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006;29:1294-1299.
31. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: Impact of changing demography and disease prevalence in the U.S. Diabetes Care. 2001;24:1936-1940.
32. Diabetes Prevention Program Research Group, Crandall J, Schade D, et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci. 2006;61:1075-1081.
33. Lindström J, Peltonen M, Eriksson JG, et al; Finnish Diabetes Prevention Study (DPS) Group. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. Diabetes Care. 2008;31:857-862.